Nautilus Biotechnology (NAUT) versus competitive financial analysis

Head-to-head comparison: Nautilus Biotechnology (NAUT) and his colleagues

Nautilus Biotechnology (NASDAQ: NAUT – Get Rating) is one of 42 public companies in the “analytical tools” industry, but how does it compare to its rivals? We will compare Nautilus Biotechnology to similar companies based on the strength of its dividends, analyst recommendations, risk, earnings, institutional ownership, valuation and profitability.

Insider and institutional ownership

47.9% of Nautilus Biotechnology’s shares are owned by institutional investors. Comparatively, 60.0% of the shares of all “analytical instruments” companies are owned by institutional investors. 13.4% of the shares of all “Analytical Tools” companies are owned by corporate insiders. Strong institutional ownership indicates that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


This table compares Nautilus Biotechnology and its competitors’ net margins, return on equity and return on assets.

Net margins Return on equity Return on assets
Nautilus Biotechnology N / A -15.57% -14.77%
Nautilus Competing biotechnologies -242.34% 8.11% -10.87%

Analyst ratings

This is a breakdown of recent recommendations for Nautilus Biotechnology and its rivals, as provided by MarketBeat.

Sell ​​ratings Keep the ratings Buy ratings Strong purchase ratings Evaluation score
Nautilus Biotechnology 0 2 2 0 2.50
Nautilus Competing biotechnologies 318 1316 1819 57 2.46

Nautilus Biotechnology currently has a consensus price target of $ 8.67, suggesting a potential upside of 131.73%. As a group, the “analytics” companies have a potential upside of 35.16%. Given Nautilus Biotechnology’s stronger consensus rating and likely higher upside, research analysts clearly believe Nautilus Biotechnology is more favorable than its rivals.

Evaluation and earnings

This table compares the gross sales, earnings per share (EPS) and valuation of Nautilus Biotechnology and its competitors.

Gross Income Net income Price / earnings ratio
Nautilus Biotechnology N / A – $ 50.31 million -6.56
Nautilus Competing biotechnologies 1.19 billion dollars $ 356.47 million -18.48

Rivals of Nautilus Biotechnology have higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


Rivals from Nautilus Biotechnology beat Nautilus Biotechnology on 8 of the 12 factors compared.

Information on Nautilus biotechnology (Get evaluation)

Nautilus Biotechnology, Inc., a developing life science company, is committed to creating a technology platform to quantify and unlock the complexity of the proteome. Develop Nautilus Platform, a proteomics platform that includes an end-to-end solution consisting of tools, consumables, and software analytics. The company was founded in 2016 and is headquartered in Seattle, Washington.

Receive news and ratings for Nautilus Biotechnology Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Nautilus Biotechnology and related companies with’s FREE daily newsletter.


Leave a Comment

Your email address will not be published.